Core Insights - Broadcom has launched BroadPeak™, a highly integrated radio digital front-end (DFE) SoC device aimed at enhancing 5G Advanced and 6G networks, featuring a 40% power reduction compared to existing solutions [1][2] - The device operates within a frequency range of 400 MHz to 8.5 GHz, making it the first product to meet the technical requirements for both 5G Advanced and 6G standards [1][2] Group 1: Product Features - BroadPeak integrates state-of-the-art 5nm CMOS DFE and ADC/DAC blocks on a single chip, enabling significant advancements in massive MIMO and remote radio head applications [1] - The SoC delivers up to 40% greater efficiency for next-generation base stations, supporting high-capacity and high-throughput networks [4] - Key specifications include a scalable RF carrier frequency range of 400 MHz to 8.5 GHz, integrated digital predistortion, and ADC/DAC sampling rates up to 19.6 GS/s [6] Group 2: Industry Impact - Massive MIMO technology is crucial for enhancing mobile network coverage, capacity, and user throughput, especially as data consumption rises due to AI-driven applications [2] - The introduction of BroadPeak allows mobile operators and OEMs to design next-generation networks that support advanced digital experiences [2] - Collaboration with partners like Altera and Hitachi GlobalLogic aims to ensure that the new technology is deployment-ready at scale, addressing the evolving demands of RAN evolution [4]

TORONTO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Income Financial Trust ("Income Financial") declares its monthly distribution of $0.08233 per unit. The distribution is payable March 10, 2026 to unit holders on record as at February 27, 2026. Under the distribution policy announced on November 18, 2013, the monthly distribution is determined by applying a 10.00% annualized rate on the volume weighted average market price (VWAP) of Income Financial's units over the last 3 trading days of the preceding month. As a ...

Agreement is first step to advance critical minerals shipment assurance, digital chain-of-custody, and authenticated marketplace transactions Atlanta, GA and Reno, NV, Feb. 19, 2026 (GLOBE NEWSWIRE) -- M2i Global, Inc. (“M2i,” the “Company,” “we,” “our” or “us”) (OTCQB: MTWO), a company specializing in the development and execution of a complete global value supply chain for critical minerals, along with Volato Group, Inc. (“Volato”) (NYSE American: SOAR), a technology-driven company, is pleased to announce ...

Core Viewpoint - Bitcoin Depot Inc. will implement a one-for-seven (1:7) reverse stock split effective February 23, 2026, at 12:01 a.m. Eastern time, with trading on a split-adjusted basis commencing the same day [1]. Group 1: Reverse Stock Split Details - The reverse stock split was authorized by stockholders holding a majority of voting power on January 12, 2026, and subsequently approved by the Board on February 12, 2026 [2]. - The reverse stock split will not change the authorized number of shares of Common Stock or preferred stock, and no fractional shares will be issued; instead, stockholders will receive cash payments for fractional shares [4]. - Following the reverse split, the exercise price for warrants will increase to $80.50, with every seven shares of Class A Common Stock purchasable under the warrants representing one share post-split [5]. Group 2: Impact on Stockholders - Stockholders will receive information from Continental Stock Transfer & Trust regarding their stock ownership after the reverse split, and those holding shares in brokerage accounts will not need to take any action [7]. - Outstanding equity-based awards and other securities convertible into Common Stock will be proportionately adjusted according to the terms specified by the Board [6]. Group 3: Company Overview - Bitcoin Depot, founded in 2016, aims to connect cash users to the digital financial system, allowing cash conversion to Bitcoin at over 9,000 kiosks globally as of August 2025 [10].

SAN DIEGO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- LPL Financial LLC announced today that financial advisor Tom Madigan, CEPA®, has joined LPL Financial’s broker-dealer, Registered Investment Advisor (RIA) and custodial platforms, aligned with Thimble Island Private Wealth, an existing firm supported by LPL Strategic Wealth (SW). He reported serving approximately $300 million in advisory, brokerage and retirement assets* and joins LPL from UBS. Based outside New Haven, Conn. in Branford, the Thimble Island team i ...

Core Insights - GBT Technologies, Inc. has announced the acquisition of twenty-three additional AI-driven health and wellness machines through its subsidiary, Cube Wellness Technologies, expanding its total to thirty-six machines [1][2] Company Overview - GBT Technologies, Inc. is focused on developing technologies in artificial intelligence (AI), Internet of Things (IoT), and intelligent platform technologies, aiming for scalable commercial applications [6] - Cube Wellness Technologies, a wholly-owned subsidiary of GBT, specializes in deploying AI-enabled automated wellness infrastructure, providing 24/7 access to health-related products [7] Expansion and Strategy - The acquisition of new machines is part of Cube Wellness' initiative to establish a scalable wellness delivery network across universities and student-focused environments nationwide [2][3] - The newly acquired machines will feature intelligent inventory management, real-time system monitoring, digital payment technologies, and data-enabled operational controls [3] - Management views this expansion as a significant milestone in transitioning Cube Wellness from initial deployment to scalable growth [4] Future Outlook - The CEO of GBT emphasizes that expanding the platform to thirty-six machines is a crucial step in building a national digital wellness infrastructure [5] - The company aims to create a technology-driven platform that enhances access to wellness services in universities and institutional environments, positioning itself within the growing sectors of healthcare access and AI-enabled retail delivery [5]

Core Viewpoint - Black Hills Corp. has filed a rate review application with the South Dakota Public Utilities Commission to recover capital infrastructure and operational costs for providing electric service to approximately 75,000 customers [1][2]. Group 1: Rate Review Application - The company is seeking $50.6 million in new annual revenue to recover about $523 million in critical investments made since the last rate review in 2014 [2]. - The investments aim to strengthen the electric grid, maintain reliability, and reduce wildfire risk [2]. Group 2: Company Background and Financial Structure - Black Hills Corp. has maintained unchanged base rates for over a decade while ensuring safe and reliable service for its customers [3]. - The capital structure for the rate review is composed of 53.2% equity and 46.8% debt, with a targeted return on equity of 10.5% [3]. - The company is requesting interim rates to take effect 180 days after the filing, with new rates expected to be finalized in the first quarter of 2027 [3]. Group 3: Company Overview - Black Hills Corp. is a growth-oriented utility company serving 1.37 million natural gas and electric utility customers across eight states [4].

Core Insights - Quantum Leap Energy LLC (QLE), a subsidiary of ASP Isotopes Inc. (ASPI), has established a Strategic Advisory Board (SAB) to enhance its capabilities in the nuclear fuel cycle [1][3] - The SAB includes industry leaders Mary Lou Dunzik-Gougar and Kevin Kramer, who bring extensive expertise in nuclear engineering and advanced materials [1][4][5] - QLE is focused on developing proprietary technologies to address inefficiencies and environmental concerns in the nuclear fuel cycle, emphasizing modular and scalable designs [2][6] Company Overview - QLE is dedicated to advancing technologies across critical segments of the nuclear fuel cycle, including uranium conversion and isotopic separation [7][8] - The company aims to fill gaps in the nuclear fuel supply chain for advanced reactors and fusion systems through exclusive rights to proprietary technologies [8] - ASP Isotopes Inc. focuses on producing isotopes for various industries, with an initial emphasis on healthcare and technology, and plans to enrich isotopes for the nuclear energy sector [9] Strategic Initiatives - The formation of the SAB is seen as a significant step in QLE's commercial evolution, expected to accelerate market entry and deepen strategic partnerships [3] - QLE intends to leverage ASPI's proprietary isotope separation technologies, which offer advantages such as reduced capital expenditure and enhanced flexibility [6] - The company has established partnerships with industry leaders like TerraPower and Fermi America to accelerate the commercialization of critical isotopes [8]

Core Insights - Ultrack Systems Inc.'s subsidiary, Better Pets, has made significant advancements in 2025, focusing on regulatory, branding, commercialization, and digital transformation milestones to expand in the growing global pet wellness industry [1] Digital Transformation - Better Pets launched an AI-powered interactive website, mybetterpets.com, enhancing user experience and reflecting the brand's commitment to regulated pet wellness products and modern consumer engagement technology [2] - The new digital platform aims to educate pet owners on product usage, provide interactive guidance for pet care selection, enhance direct-to-consumer conversion, and support scalable e-commerce growth [11] Market Opportunity - The global pet care market is projected to exceed $250 billion by the end of the decade, driven by increased pet humanization, premiumization, and rising demand for regulated wellness products [3] - Topical care and health-support categories are among the fastest-growing segments in regulated markets, particularly in Canada and the United States [3] Product Focus and Regulatory Milestones - Better Pets confirmed ownership of over seven formulations and narrowed its commercialization focus to Pet Balm, facilitating a capital-efficient market entry [4] - The company achieved a major regulatory milestone by receiving Health Canada Veterinary Product Notification numbers for two products, validating compliance with Canadian standards [4] Brand and Distribution Strategy - Better Pets engaged Empire Media Worx for a brand modernization initiative, completing multiple branding concepts and production-ready labeling [9] - The company has developed a hybrid distribution model combining direct-to-consumer e-commerce and distributor-supported retail expansion, with Freedom Pet Supplies agreeing to carry Better Pets products in approximately 1,800–2,000 retail locations [10] Growth Strategy for 2026 - With regulatory approvals secured and digital infrastructure launched, Better Pets is focused on execution in 2026, planning initiatives for portfolio updates and market entry evaluations [12][16] - Management believes the combination of regulatory compliance, digital infrastructure, and brand modernization positions Better Pets to capitalize on the accelerating global pet wellness market and drive long-term shareholder value [13]

Group 1 - Moleculin Biotech, Inc. has entered into agreements for the immediate exercise of existing warrants to purchase up to 2,122,652 shares of common stock at an exercise price of $3.90 per share, expected to generate approximately $8.3 million in gross proceeds [1][4] - Roth Capital Partners is acting as the financial advisor for this transaction [2] - The company will issue new unregistered warrants for up to 6,367,956 shares, exercisable at the lesser of $3.90 or the lowest volume weighted average price during the next five trading days, subject to shareholder approval [3] Group 2 - The transaction is expected to close on or about February 20, 2026, pending customary closing conditions, with net proceeds intended for working capital and general corporate purposes [4] - The new warrants were offered in a private placement and have not been registered under the Securities Act of 1933, with the company agreeing to file a registration statement for the resale of shares [5] Group 3 - Moleculin Biotech is a Phase 3 clinical stage pharmaceutical company focused on developing therapeutic candidates for hard-to-treat tumors and viruses, with its lead program Annamycin targeting relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases [7][8] - The company has initiated the MIRACLE Trial, a pivotal Phase 3 trial evaluating Annamycin in combination with cytarabine for the treatment of relapsed or refractory acute myeloid leukemia, following a successful Phase 1B/2 study [8] - Additionally, the company is developing WP1066, an immune/transcription modulator targeting various cancers, and has a portfolio of antimetabolites including WP1122 for potential treatment of pathogenic viruses [9]